Drug Search Results
More Filters [+]

Rosabulin

Alternative Names: rosabulin, sta-5312, sta5312, sta 5312
Latest Update: 2014-02-03
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Tubulin Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Madrigal
Company Location: WEST CONSHOHOCKEN PA 19428
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Rosabulin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Oncology Hematological Unspecified|Oncology Solid Tumor Unspecified|Leukemia|Lymphoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT00276913

P1

Completed

Oncology Hematological Unspecified|Oncology Solid Tumor Unspecified

None

NCT00088101

P1

Completed

Leukemia|Lymphoma

None

Recent News Events

Date

Type

Title